Corporate Finance

Needham is solely focused on growth companies and their investors

Why Needham Corporate Finance?

Needham & Company, LLC recognizes that as a growth company, you require dynamic investment banking services that are unique and practical. Our investment banking group is focused on delivering creative, independent solutions to the growth companies of today and tomorrow. Needham’s expertise extends beyond the United States to various markets globally, such as China, Europe and Israel. Needham’s broad-based investment banking capabilities include public and private equity capital raises and strategic advisory services. A long history of meaningful relationships, deep industry knowledge and focused expertise enables us to provide sound guidance and support in an often turbulent, constantly evolving business environment.

As an employee-owned entrepreneurial firm, Needham is driven by client relationships. We approach each engagement as an opportunity to establish a long lasting partnership that will endure well beyond the immediacy of the transaction. It is this philosophy that has given hundreds of public and private companies worldwide the confidence to rely on Needham for their investment banking needs.

Needham’s investment banking group is committed to companies with market capitalizations less than $5 billion. Our core knowledge and deep domain expertise is concentrated in the following industry verticals:

  • Clean Technology
  • Communications
  • Financial Services
  • Enterprise Infrastructure
  • Healthcare
  • Industrial & Diversified Growth
  • Internet, Digital Media & Consumer
  • Semiconductors & Semiconductor Capital Equipment
  • Software & Services

By serving a focused customer base, we offer a high level of client service and extensive attention from experienced senior professionals and management throughout the entire lifecycle of a transaction.

  • UnboundID provides the industry’s leading software platform for customer identity and access management. Enterprise customers select the UnboundID Platform to modernize traditional Identity and Access Management systems, and enable new customer-facing digital business initiatives that provide real-time personalization and delivery of a consistent customer experience across channels and devices. Some of the world’s largest and most demanding companies in financial services, retail, hospitality, telecommunications and healthcare rely on UnboundID to manage and protect their identity and preference data across application portfolios and systems of engagement. UnboundID customers consistently report a total cost of ownership savings between 25 to 90 percent relative to legacy directory servers, and the company enjoys a 100% customer renewal rate.

    UnboundID, a market leading provider of customer identity and access management software, to help enterprises improve customer engagement, completed its sale to Ping Identity, the leader in Identity Defined Security. Terms of the transaction were not disclosed. The deal puts Ping Identity, which is owned by Vista Equity Partners, firmly in at the intersection of identity and customer engagement and management. The combined company provides Identity and Access Management solutions for the world’s leading companies, including over half of the Fortune 100, and manages over 3 billion identities. Needham & Company acted as the exclusive financial advisor to UnboundID.

  • Ellie Mae, Inc. (NYSE:ELLI) is a leading provider of innovative on-demand software solutions and services for the residential mortgage industry. Mortgage lenders of all sizes use Ellie Mae’s Encompass® all-in-one mortgage management solution, Mavent Compliance Service, and AllRegs research, reference and education resources to improve compliance, loan quality and efficiency across the entire mortgage lifecycle.

    Ellie Mae, Inc. raised $284.63 million in its follow-on offering at $90.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 412,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Ellie Mae, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Argos Therapeutics (NASDAQ: ARGS) is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.

    Argos Therapeutics, Inc. raised $50.0 million in its follow-on offering at $5.50 per share of common stock and accompanying warrants . Needham acted as the lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Argos Therapeutics, Inc. to fund their pivotal Phase 3 ADAPT trial of AGS-003, the ongoing and planned investigator-initiated Phase 2 clinical trials of AGS-003, their share of the expected costs of the leasing, build-out and equipping of a commercial manufacturing facility and activities in preparation for the submission of a BLA to the FDA for AGS-003, and for working capital and other general corporate purposes.

  • Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.

    Nicox S.A. completed the pricing of an offering a reserved capital increase of ordinary shares of the Company to a specific category of investors. The gross proceeds of the financing are approximately €18 million, for a total of 2,064,000 million new shares. Needham acted as lead placement agent for this transaction. The net proceeds from the sale of the Units will be used by Nicox S.A. for clinical development of pipeline candidates (NCX 4251 in blepharitis and NCX 470 in glaucoma), working capital and general corporate purposes.

  • Impinj (NASDAQ: PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers’ licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items’ unique identity, location and authenticity, or Item Intelligence™, to the digital world, which Impinj believes is the essence of the Internet of Things.

    Impinj, Inc. raised $77.3 million in its upsized initial public offering at $14.00 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 720,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Impinj, Inc. to repay $5.0 million of indebtedness under the mezzanine credit facility and the remainder will be used for working capital and other general corporate purposes.

  • FormFactor, Inc. (NASDAQ: FORM) helps semiconductor manufacturers test the integrated circuits (ICs) that power consumer mobile devices, as well as computing, automotive and other applications. The company is one of the world’s leading providers of essential wafer test technologies and expertise, with an extensive portfolio of high-performance probe cards for DRAM, Flash and SoC devices. Customers use FormFactor’s products and services to lower overall production costs, improve their yields and enable complex next-generation ICs. Headquartered in Livermore, California, the company services its customers from a network of facilities in Europe, Asia and North America.

    FormFactor, Inc. (Nasdaq:FORM) announced that it has completed the acquisition of Cascade Microtech, Inc. (NASDAQ: CSCD),a worldwide leader in precision contact, electrical measurement and test of integrated circuits (ICs), optical devices and other small structures, for a net purchase price of $352 million in cash and stock. Needham & Company acted as the exclusive financial advisor and provided a fairness opinion to the Board of Directors of FormFactor, Inc. as part of its services.

  • Selecta Biosciences, Inc. (NASDAQ: SELB) is a clinical-stage biopharmaceutical company developing targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) technology is a highly flexible nanoparticle platform, capable of incorporating a wide range of antigens and immunomodulators, allowing the SVP products to either induce antigen-specific tolerance or activate the immune system. Selecta's focus is on developing and commercializing differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases by mitigating the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Tolerance-inducing SVP products also have potential applications in the treatment of allergies and autoimmune diseases. Selecta is also developing SVP products that activate the immune system to prevent and treat cancer, infections and other diseases. Selecta is based in Watertown, Massachusetts, USA.

    Selecta Biosciences, Inc. raised $74.1 million in its upsized initial public offering at $14.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 289,633 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Selecta Biosciences to support the clinical development of SEL-212, conduct preclinical studies in order to advance the development of Selecta’s other SVP product candidates and for working capital and general corporate purposes.

  • SCYNEXIS, Inc. (NASDAQ: SCYX) is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. SCYNEXIS is developing its lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.

    SCYNEXIS, Inc. raised $22.5 million in its follow-on offering of 9,375,000 shares of its common stock and warrants to purchase 4,218,750 shares of its common stock. The shares and warrants are being sold at a public offering price of $2.40 per share. The shares of common stock and warrants will be issued separately. The warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $3.00 per share. Needham acted as the co-lead manager on the transaction. The net proceeds from the sale of the shares and warrants from the offering will be used by SCYNEXIS, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and strategic acquisitions.

  • Medgenics, Inc. (NYSE: MDGN) is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. Medgenics is also the developer of TARGT™ (Transduced Autologous Restorative Gene Therapy), a proprietary gene therapy platform.

    Medgenics, Inc. raised $21.1 million in its follow-on offering at $5.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 196,363 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Medgenics, Inc. to fund (i) product development activities, including the development of companion diagnostics for existing programs, (ii) patent maintenance fees and intellectual property support, (iii) licensing and research collaborations and (iv) general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses.

  • GigPeak, Inc. (NYSE MKT:GIG) is a leading innovator of semiconductor ICs and software solutions for high-speed connectivity and high-quality video compression over the Network and the Cloud. The focus of the company is to develop and deliver products that enable lower power consumption and faster data connectivity, more efficient use of network infrastructure, broader connectivity to the Cloud, and reduce the total cost of ownership of existing network pipes from the core to the end user. GigPeak addresses both the speed of data transmission and the amount of bandwidth the data consumes within the network, and provides solutions that increase the efficiency of the Internet of Things, leveraging its strength in high-speed connectivity and high quality video compression. The extended product portfolio provides more flexibility to support changing market requirements from ICs and MMICs through full software programmability and cost efficient custom ASICs.

    GigPeak, Inc. raised $28.8 million in its follow-on offering at $2.00 per share. Needham acted as a joint bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,875,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by GigPeak, Inc. for potential acquisitions for strategic growth, including to acquire critical technologies and scalable businesses. It intends to focus on multiple global attractive acquisition targets.

  • Dermira, Inc. (NASDAQ:DERM) is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and DRM01, in Phase 2b development for the treatment of facial acne vulgaris. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. raised $144.9 million in its follow-on offering at $28.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dermira, Inc. will enable the Company to complete and generate topline results from their ongoing Phase 3 clinical trials for Cimzia and their planned Phase 3 clinical trials for DRM01; complete the ARIDO trial and other registration-enabling activities and submit an NDA to the FDA for potential approval related to DRM04; enable UCB to submit a supplemental Biologics License Application to the FDA for potential approval of Cimzia; and commercialize at least one of their product candidates assuming that the Company receives the necessary regulatory approvals.

  • Clearside Biomedical, Inc. (NASDAQ: CLSD), is a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space (SCS™) microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye.

    Clearside Biomedical, Inc. raised $50.4 million in its initial public offering at $7.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 948,843 shares of common stock at the initial public offering price to cover over-allotments.The net proceeds from the sale of the shares will be used by Clearside Biomedical, Inc. for funding of the Company’s pivotal Phase 3 clinical trial of CLS-1001, its Phase 2 clinical trial of CLS-1003 and its preparation of an IND for, and subsequent Phase 1/2 clinical trial of, CLS-1002. The remaining proceeds will be used for the continued research and development of earlier-stage programs, and for working capital and general corporate purposes.

  • RADCOM (NASDAQ: RDCM) is a first-mover and leading provider of NFV-ready service assurance and customer experience management solutions for Communications Service Providers (CSPs). RADCOM's software - MaveriQ - continuously monitors network performance and quality of services, to optimize user experience for CSPs' subscribers. RADCOM specializes in solutions for next-generation mobile and fixed networks, including LTE, VoLTE, IMS and others. MaveriQ enables CSPs to smoothly migrate their networks to NFV by assuring physical, NFV-based and hybrid networks.

    RADCOM Ltd. raised $23.0 million in its follow-on offering at $11.00 per share. Needham acted as the lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 272,727 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by RADCOM for general corporate purposes, which may include financing its operations, capital expenditures and business development.

  • Acacia Communications (NASDAQ: ACIA) develops, manufactures and sells high-speed coherent optical interconnect products that are designed to transform communications networks through improvements in performance, capacity and cost. By converting optical interconnect technology to a silicon-based technology, a process Acacia refers to as the "siliconization of optical interconnect," Acacia is able to offer products that meet the needs of cloud and service provider customers in a simple, open, high-performance form factor that can be easily integrated in a cost-effective manner with existing network equipment.

    Acacia Communications, Inc. raised $119.03 million in its initial public offering at $23.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Acacia Communications for for working capital and general corporate purposes. Acacia Communications will not receive any of the proceeds from any sale of shares by the selling stockholders.

  • Solair is an Italian provider of an innovative IoT software platform to customers across a number of industries, including manufacturing, retail, food & beverage and transportation.

    Solair, an Italian provider of an innovative IoT software platform to customers across a number of industries, including manufacturing, retail, food & beverage and transportation, completed its previously announced sale to Microsoft Corporation (NASDAQ: MSFT), a multinational technology company that develops, manufactures, licenses, supports and sells computer software, consumer electronics and personal computers and services. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to Solair.

  • Rocketick Technologies, Ltd. is an Israel-based pioneer and leading provider of multicore parallel simulation. Rocketick’s market-leading technology achieves linear speed-up by parallelizing simulation on standard x86-based multicore servers, providing automated partitioning across designs and testbenches, and the flexibility to direct simulations to server farm resources ranging from one to 64 cores. It also provides a significant accuracy advantage and enhanced visibility with four-state logic simulation, and reduces host memory footprint by 2-3X for gate-level designs.

    Rocketick Technologies, Ltd., an Israel-based pioneer and leading provider of multicore parallel simulation, completed its previously announced sale to Cadence Design Systems, Inc. (NASDAQ: CDNS), a technology company that enables global electronic design innovation and plays an essential role in the creation of today's integrated circuits and electronics. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to Rocketick Technologies, Ltd..

  • Aeglea (NASDAQ: AGLE) is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

    Aeglea BioTherapeutics, Inc. raised $54.82 million in its upsized initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 481,940 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Aeglea BioTherapeutics, Inc. for general corporate purposes including working capital, product development and operating expenses.

  • Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), with locations in Ewing, N.J., and Vancouver, B.C., is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations of anti-cancer drugs, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensuring exposure of this ratio to the tumor. Celator's lead product is VYXEOS™ (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin in Phase 3 clinical testing for the treatment of acute myeloid leukemia. We have also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. More recently, the Company has advanced its CombiPlex platform and broadened its application to include molecularly targeted therapies.

    Celator Pharmaceuticals, Inc. raised $43.7 million in its follow-on offering at $9.50 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Celator Pharmaceuticals, Inc. to fund initial launch activities, commercialization of VYXEOS, advance the pipeline of clinical stage assets and for general corporate purposes.

  • ANADIGICS, Inc. (NASDAQ: ANAD) designs and manufactures innovative radio frequency (RF) solutions for the growing CATV infrastructure, small-cell, WiFi, and cellular markets. Headquartered in Warren, NJ, ANADIGICS offers RF products with exceptional reliability, performance and integration to deliver a unique competitive advantage to OEMs and ODMs for infrastructure and mobile applications. The Company’s award-winning solutions include line amplifiers, upstream amplifiers, power amplifiers, front-end ICs, front-end modules and other RF components.

    ANADIGICS, Inc. (NASDAQ: ANAD), a world leader in radio frequency (RF) solutions, completed its previously announced sale to II‐VI Incorporated (NASDAQ: IIVI), a leader in engineered materials and optoelectronic components for approximately $78.2 million in cash. Needham & Company acted as the exclusive financial advisor to ANADIGICS, Inc.

  • IntegriChain is the leading channel management cloud used by life sciences suppliers, including nine of the top 10 pharmaceutical manufacturers, to drive channel collaboration and to improve the efficiency of how products reach customers. Pharmaceutical, biopharm/specialty pharma, generics, and consumer health suppliers use IntegriChain to manage their supply chain relationships, inventories, and orders across a vast network of retailers, ecommerce, and distributors. As a suite of informed applications and analytics built on top of aggregated channel inventory and point-of-sale (POS) data, IntegriChain provides customer operations, national accounts, and finance teams with a collaborative, agile, and mobile alternative to ERP and homegrown systems. By embedding big-data customer insights into daily business processes, IntegriChain helps control the high cost of product distribution while improving product availability, ensuring a higher level of revenue predictability and maximizing distribution investment. More than $200 billion in annual U.S. commerce and 2 billion transactions flow through the IntegriChain Cloud annually. IntegriChain is backed by Accel-KKR, a leading technology private equity firm.

    IntegriChain, the leading channel management cloud used by life sciences suppliers has received a strategic equity investment from Accel-KKR, a technology-focused investment firm with $4.0 billion in capital commitments to its current funds. Under the terms of the investment, Accel-KKR will acquire 100% of the equity not held by members of IntegriChain's management team. Needham & Company acted as the exclusive financial advisor to IntegriChain.

  • ThermiGen LLC is a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. The Thermi flagship product is the ThermiRF®, Temperature Controlled Radio Frequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF®, is an advanced technology using finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market.

    ThermiGen LLC, a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications, completed its previously announced sale to Almirall, S.A., a global pharmaceutical company based in Barcelona, Spain. In September 2015, Almirall acquired a minority stake in ThermiGen for $5 million representing 7.7% of the share capital of the company and paid $2.5 million in exchange of a call option right to acquire up to 100% of the company for an Enterprise Value of approximately $80 million. The call option to acquire 100% of the share capital of ThermiGen LLC was exercised by Almirall. Needham & Company acted as the exclusive financial advisor to ThermiGen LLC.

  • PMC (NASDAQ: PMCS) is the semiconductor and software solutions innovator transforming networks that connect, move and store big data. Building on a track record of technology leadership, PMC is driving innovation across storage, optical and mobile networks. PMC's highly integrated solutions increase performance and enable next-generation services to accelerate the network transformation.

    PMC-Sierra, Inc., a leading innovator of energy-saving films and glass products for automotive and architectural markets, completed its previously announced sale to Microsemi Corporation (Nasdaq: MSCC) ("Microsemi"), a leading provider of semiconductor solutions differentiated by power, security, reliability and performance. Under the terms of the agreement, PMC-Sierra's shareholders have received $9.22 in cash and 0.0771 of a share of Microsemi common stock for each share of PMC common stock through an exchange offer. Needham & Company acted as a financial advisor to PMC-Sierra, Inc.

  • Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceutical, Inc. raised $55.0 million in its follow-on offering at $20.00 per share. Needham acted as co-lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia has completed Phase 2 development of its lead product candidate, vadadustat (formerly AKB-6548), an oral therapy for the treatment of anemia related to CKD in both non-dialysis and dialysis patients. Enrollment in the PRO2TECT™ Phase 3 program in non-dialysis patients commenced in late 2015 and the INNO2VATE™ Phase 3 program in dialysis-dependent CKD patients is expected to commence in 2016.

    Akebia Therapeutics, Inc. raised $65.3 million in its follow-on offering at $9.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. offering to fund continued clinical development of vadadustat in patients with anemia secondary to chronic kidney disease (CKD), including to prepare, initiate and conduct its PRO2TECT™ Phase 3 program and to prepare and initiate its planned INNO2VATE™ Phase 3 program, to advance AKB-6899 through Phase 1 development in oncology, and the remainder for working capital and other general corporate purposes.

  • ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which we have submitted a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA and which has the potential to be the first drug approved in the United States for this condition. The FDA has classified the NUPLAZID NDA as having Priority Review status. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain.

    ACADIA Pharmaceuticals Inc. raised $300.0 million in its follow-on offering at $29.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals Inc. . to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

  • Cempra, Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C.

    Cempra, Inc. raised $100.0 million in its follow-on offering at $24.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Cempra, Inc. to fund the commercial launch of solithromycin in community acquired bacterial pneumonia (CABP) in the U.S., subject to the drug receiving FDA approval for such an indication, research and development activities, including the continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in acute bacterial skin and skin structure infections (ABSSSI) and also for the chronic oral treatment of refractory infections in bones and joints, as well as for working capital and general corporate and administrative expenses.

  • Yirendai (NYSE: YRD) is a leading online consumer finance marketplace in China connecting investors and individual borrowers. The Company provides an effective solution to address largely underserved investor and individual borrower demand in China through an online platform that automates key aspects of its operations to efficiently match borrowers with investors and execute loan transactions. Yirendai deploys a proprietary risk management system, which enables the Company to effectively assess the creditworthiness of borrowers, appropriately price the risks associated with borrowers, and offer quality loan investment opportunities to investors. Yirendai's online marketplace provides borrowers with quick and convenient access to consumer credit at competitive prices and investors with easy and quick access to an alternative asset class with attractive returns.

    Yirendai Ltd. raised $75 million in its initial public offering at $10.00 per share. Needham acted as a passive bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Yirendai Ltd. for general corporate purposes, which may include investment in product development, sales and marketing activities, technology infrastructure, capital expenditures, improvement of corporate facilities and other general and administrative matters. The company may also use a portion of these proceeds for the acquisition of, or investment in, technologies, solutions or businesses that complement the company’s business.

  • Pertino is a new way to WAN for the mobile and cloud era—secure, software-defined and delivered as a service. Mobile and cloud technologies are transforming IT, resulting in a hybrid IT model where distributed workforces and workloads are reliant on the Internet. Our Cloud Network Engine platform enables enterprises to build and manage private cloud networks that overlay the public Internet, securely connecting people, devices and resources anywhere. With AppScape, our network services app store, Pertino cloud networks can be extended with enterprise-level visibility, security and control services. This modern approach to networking combines the power and pervasiveness of the cloud with SDN and virtualization technologies to eliminate cost and complexity. Finally, a WAN that is cloud-agile and works the way organizations work today, without hardware, hassles, or high costs. Founded in 2011, Pertino is venture funded by premier firms and headquartered in Los Gatos, California.

    Pertino, a privately-held Silicon Valley company that has pioneered the use of software-defined networking to deliver cloud-based networks as-a-service for enterprise and SMB customers worldwide, completed its previously announced sale to Cradlepoint, the global leader in software-defined 4G LTE network solutions for enterprises. The terms of the transaction were not disclosed. Needham & Company acted as the exclusive financial advisor to Pertino.

  • The Chinese consortium of investors was led by SummitView Capital and includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management. Summitview Capital is a private equity firm specializing in buyouts. It focuses on technology, media and telecommunications, clean technology, semiconductors, and modern information service industry. Summitview Capital is based in Shanghai China, with an additional office in Changzhou, China.

    A Chinese consortium of investors led by SummitView Capital and that includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management announced that it has completed the acquisition of Integrated Silicon Solution, Inc. (NASDAQ: ISSI), a global fabless semiconductor company, for a net purchase price of $782.6 million in cash. Needham & Company acted as a financial advisor to the Chinese consortium.

  • Inphi Corporation (NYSE: IPHI) is a leading provider of high-speed, mixed-signal semiconductor solutions for the communications, computing and data center markets. Inphi’s end-to-end data transport platform delivers high signal integrity at leading-edge data speeds, addressing performance and bandwidth bottlenecks in networks, from fiber to memory. Inphi’s solutions minimize latency in computing environments and enable the rollout of next-generation communications infrastructure. Inphi’s solutions provide a vital interface between analog signals and digital information in high-performance systems, such as telecommunications transport systems, enterprise networking equipment, enterprise and data center servers, and storage platforms.

    Inphi Corporation issued $230.0 million principal amount of Convertible Senior Notes due 2020. The size of the offering was increased to $200.0 from the previously announced $150.0 million aggregate principal amount. Prior to June 1, 2020, the notes will be convertible only under certain circumstances and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The initial conversion rate for the notes will be 24.8988 shares per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $40.16 per share, and will be subject to adjustment upon the occurrence of certain events. The initial conversion price represents a conversion premium of approximately 35.0% over the last reported sale price of $29.75 per share of Inphi's common stock on The New York Stock Exchange on December 2, 2015. Inphi will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. In addition, holders may require Inphi to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. The underwriters fully exercised their option to purchase an additional $30 million in aggregate principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction.

  • Instructure, Inc. (NYSE: INST) is a leading software-as-a-service (SaaS) technology company that makes software that makes people smarter. With a vision to help maximize the potential of people through technology, Instructure created Canvas and Bridge to enable organizations everywhere to easily develop, deliver and manage engaging face-to-face and online learning experiences. To date, Instructure has connected millions of teachers and learners at more than 1,800 educational institutions and corporations throughout the world.

    Instructure, Inc. raised $81.0 million in its initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 660,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Instructure, Inc. for general corporate purposes, including working capital, sales and marketing activities, research and development activities, general and administrative matters and capital expenditures. They may also use a portion of the net proceeds from this offering for acquisitions of, or investments in, technologies, solutions or businesses that complement the business.

  • Xoom Corporation (NASDAQ: XOOM) is a leading digital money transfer provider that enables consumers to send money, pay bills and send mobile reloads to family and friends around the world in a secure, fast and cost-effective way, using their mobile phone, tablet or computer. During the 12 months ended March 31, 2015, Xoom’s more than 1.3 million active customers sent approximately $7.0 billion with Xoom.

    Xoom Corporation, a digital money transfer provider, completed its previously announced sale to PayPal, Inc. (NASDAQ: PYPL), a provider of a worldwide online payments system. In accordance with the terms of the acquisition agreement announced on July 1, 2015, PayPal acquired all of the outstanding shares of Xoom for $25 per share in cash. Xoom will operate as a separate service within PayPal. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Xoom Corporation as part of its services.

  • Xtera Communications, Inc. (NASDAQ: XCOM) is a leading provider of high-capacity, cost-effective optical transport solutions, supporting the high growth in global demand for bandwidth. Xtera sells solutions to telecommunications service providers, content service providers, enterprises and government entities worldwide. Xtera’s proprietary Wise RamanTM optical amplification technology leads to capacity and reach performance advantages over competitive products. Xtera’s solutions enable cost-effective capacity to meet customers’ bandwidth requirements of today and to support their increasing bandwidth demand fueled by the development of data centers and related cloud-based services.

    XTERA Communications Inc. raised $25.0 million in its offering at $5.00 per share. Needham acted as the lead bookrunner on the transaction. The net proceeds from the sale of the shares will be used by XTERA Communications Inc. for working capital and other general corporate purposes, including to finance our expected growth, develop new products or fund capital expenditures. The Company may also use a portion of the net proceeds to repay borrowings under its credit facility or term loan, or to expand its existing business through acquisitions of other businesses, products or technologies.

  • LendingTree, Inc. (NASDAQ: TREE) operates a leading online loan marketplace and provides consumers with an array of online tools and information to help them find the best loans for their needs. The Company's online marketplace connects consumers with multiple lenders that compete for their business, empowering consumers as they comparison-shop across a full suite of loans and credit-based offerings. The Company provides access to lenders offering home loans, home equity loans/lines of credit, reverse mortgages, personal loans, auto loans, small business loans, credit cards, student loans and more.

    LendingTree, Inc. raised $112.41 million in its follow-on offering at $115.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 127,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by LendingTree, Inc. for general corporate purposes, including but not limited to, working capital and potential acquisitions.

  • iboss Cybersecurity defends today’s large, distributed organizations against targeted cyber threats which lead to data loss, with the iboss next-gen Secure Web Gateway Platform, leveraging innovative cloud architecture and patented advanced threat defense technologies. iboss advanced solutions deliver unparalleled visibility across all inbound/outbound data channels, and include security weapons that reveal blind spots, detect breaches and minimize the consequences of data exfiltration. With leading threat protection and unsurpassed usability, iboss is trusted by thousands of organizations and millions of users.

    iBoss, Inc. raised $35.0 million in Series A funds from Goldman Sachs’ Private Capital Investing group. The new financing will allow iboss to aggressively develop groundbreaking technology, including the rollout of its next-generation cloud platform, while continuing to expand globally. Needham acted as the sole placement agent for this transaction.

  • Adesto Technologies Corporation (NASDAQ: IOTS) offers the world’s lowest power memory solutions unleashing innovation for a new class of connected applications and previously unimagined devices. The company has designed and built a portfolio of innovative products, including Fusion Serial Flash, DataFlash® and Mavriq™ serial memory. Adesto holds more than 100 patents with dozens more in process and is working with visionary companies across various industries to deploy its technology to the market.

    Adesto Technologies Corporation raised $25.0 million in its initial public offering at $5.00 per share. Needham acted as the lead bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Adesto Technologies Corporation use the net proceeds from this offering for working capital and other general corporate purposes, to acquire or invest in complementary businesses, products, services, technologies or other assets, and for potential pay down of a $15.0 million term loan facility.

  • Intronis provides data protection solutions for small businesses, delivered exclusively through the IT channel. The Intronis ECHOplatform securely protects physical and virtual data with native support for physical imaging,VMware, Hyper-V, Exchange, and SQL, all through a re-brandable central management console that integrates with major RMM and PSA tools. With Intronis' fixed-fee storage pricing per SMB account, IT service providers are able to streamline their pricing strategy and simplify their account management.

    Intronis, Inc. (NASDAQ: SWTX), a leader in providing data protection solutions to managed service providers (MSPs), a fast-growing channel delivering IT services to small and medium-sized businesses, completed its previously announced sale to Barracuda Networks, Inc. (NYSE: CUDA), a provider of cloud-connected security and storage solutions that simplify IT, in an all cash transaction. Needham & Company acted as a financial advisor to Intronis, Inc..

  • Netsertive’s digital marketing intelligence platform empowers brands and local businesses to work together to win local customers. The company’s two complementary solutions, MarketWise™ for Brands and StreetWise™ for Local Businesses, enable cooperative marketing and resource sharing between brands and their local business partners. Both are powered by Netsertive's proprietary learning engine, which combines the company's deep industry experience with the collective intelligence of its extensive network of automotive, IT technology, major appliance, furniture, consumer electronics and healthcare clients to deliver unprecedented campaign speed, performance and value. An award-winning marketing technology company and Google Premier SMB Partner, Netsertive drives local marketing success from campaign enablement through scaled, local execution. Additionally, Netsertive helps brands with their co-op marketing to ensure localized brand compliance, seamless campaign execution and reimbursement tracking for local partners. Founded in 2009 and based in Research Triangle Park, North Carolina, the company has a history of rapid growth, a world-class team and the strength of venture capital funding from top firms RRE Ventures, Harbert Venture Partners, River Cities Capital Funds and Greycroft Partners. Netsertive was named 2014 Software Company of the Year by North Carolina Technology Association and was named among Inc. Magazine’s 500 fastest-growing private companies three years in a row.

    Netsertive raised $15 million in Series C growth financing. River Cities Capital Funds led the round and will be joined by existing investors. The new round will fuel Netsertive’s acceleration in the digital marketing technology arena, as it continues to add major brands for its MarketWise™ solution and local businesses for its StreetWise™ solution. Needham & Company served as exclusive placement agent on this transaction.

  • Sarepta Therapeutics (NASDAQ: SRPT) is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases.

    Sarepta Therapeutics, Inc. (NASDAQ: SRPT) raised $126.8 million in its follow-on offering at $39.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Sarepta Therapeutics, Inc. for product and commercial development, manufacturing, any business development activities and for general corporate purposes.

  • Dot Hill Systems Corp. (NASDAQ: HILL) solves today's storage workload challenges created by the Internet of Things and third platform technologies leveraging its proprietary AssuredSAN family of hybrid storage solutions with RealStor, the next generation real-time storage operating system. In today's interconnected world, Dot Hill storage solutions support people accessing information, and machines collecting sensor data, all in real time. Dot Hill's solutions combine innovative intelligent software with the industry's most flexible and extensive hardware platform and simplified management to deliver best-in-class solutions. Headquartered in Longmont, Colo., Dot Hill has offices and/or representatives in the United States, Europe, and Asia.

    Dot Hill Systems Corp. (NASDAQ: HILL), a leading innovator of energy-saving films and glass products for automotive and architectural markets, completed its previously announced sale to Seagate Technology plc (NASDAQ: STX), a world leader in storage solutionsin an all cash transaction. Needham & Company acted as a financial advisor to Dot Hill Systems and provided a fairness opinion to its Board of Directors as part of its services.

  • Medgenics, Inc. (NASDAQ: MDGN) is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases.

    Medgenics, Inc. raised $46.01 million in its follow-on offering at $6.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 923,250 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Medgenics, Inc. for for product development activities, including (a) the development of technologies acquired in the previously announced acquisition of neuroFix, LLC, (b) patent maintenance fees and intellectual property support, (c) licensing and research collaborations and (d) general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses and making certain payments in connection with the acquisition of neuroFix, LLC, including an expected $2.8 million payment to satisfy a specific corporate milestone payment to the former stockholders of neuroFix, LLC.

  • Ikanos Communications, Inc. (NASDAQ: IKAN) is a leading provider of advanced broadband semiconductor and software products for the connected home. The company’s broadband DSL, communications processors and other offerings power access infrastructure and customer premises equipment for many of the world’s leading network equipment manufacturers and telecommunications service providers.

    Ikanos Communications, Inc. (NASDAQ: IKAN), a high performance broadband networking semiconductor and software provider enabling both central office and home gateway solutions, completed its previously announced sale to Qualcomm Incorporated (NASDAQ: QCOM), a world leader in 3G, 4G and next-generation wireless technologies. Pursuant to the agreement, Qualcomm Atheros, through a wholly-owned subsidiary, acquired all of the issued and outstanding shares of common stock of Ikanos for $2.75 per share in cash, and assumed all outstanding indebtedness at the closing of the transaction. Needham & Company acted as a financial advisor to Ikanos and provided a fairness opinion to the Board of Directors of Ikanos as part of its services. .

  • 2U, Inc. (NASDAQ: TWOU) partners with leading colleges and universities to deliver the world's best online degree programs so students everywhere can reach their full potential. Our Platform, a fusion of cloud-based software-as-a-service technology and technology-enabled services, provides schools with the comprehensive operating infrastructure they need to attract, enroll, educate, support and graduate students globally.

    2U, Inc. (NASDAQ: TWOU) raised $136.9 million in its follow-on offering at $34.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 525,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by 2U, Inc. for general corporate purposes, including expenditures for program marketing, sales, technology, and content development, in connection with new program launches and growing existing programs.

  • Q2 Holdings, Inc. (NASDAQ: QTWO) is a leading provider of secure, cloud-based virtual banking solutions headquartered in Austin, Texas. Q2 enables regional and community financial institutions, or RCFIs, to deliver a robust suite of integrated virtual banking services and engage more effectively with their retail and commercial account holders who expect to bank anytime, anywhere and on any device. Q2 solutions are often the most frequent point of interaction between its RCFI customers and their account holders. As such, Q2 purpose-built its solutions to deliver a compelling, consistent user experience across digital channels and drive the success of its customers by extending their local brands, enabling improved account holder retention and creating incremental sales opportunities.

    Q2 Holdings, Inc. (NASDAQ: QTWO) raised $111.41 million in its follow-on offering at $25.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 569,850 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Q2 Holdings for general corporate purposes and working capital, including to finance their expected growth, develop new technologies, fund capital expenditures, or expand their existing business through investments in or acquisitions of other businesses or technologies.

  • Paylocity Holding Corporation (NASDAQ: PCTY) is a provider of cloud-based payroll and human capital management, or HCM, software solutions for medium-sized organizations. Paylocity's comprehensive and easy-to-use solutions enable its clients to manage their workforces more effectively. Paylocity's solutions help drive strategic human capital decision-making and improve employee engagement by enhancing the human resource, payroll and finance capabilities of its clients.

    Paylocity Holding Corporation (NASDAQ: PCTY) raised $128.0 million in its follow-on offering at $29.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 561,000 shares of common stock at the follow-on offering price to cover over-allotments. The shares of common stock offered by this prospectus are being registered for the account of the selling stockholders named in the prospectus. As a result, all proceeds from the sales of the common stock will go to the selling stockholders and Paylocity will not receive any proceeds from the resale of the common stock by the selling stockholders.

  • Nabriva Therapeutics AG (NASDAQ: NBRV) is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans.

    Nabriva Therapeutics AG (NASDAQ: NBRV) raised $106.1 million in its initial public offering at $10.25 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,350,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Nabriva to complete the clinical development of lefamulin for CABP, to submit applications for marketing approval for lefamulin for CABP in both the United States and Europe, to pursue the clinical development of lefamulin for additional indications, for earlier stage research and development activities and for working capital and other general corporate purposes.

  • Synacor (NASDAQ:SYNC) is the trusted technology development, multiplatform services and revenue partner for video, internet and communications providers, device manufacturers, and enterprises. We deliver modern, multiscreen experiences and advertising to their consumers that require scale, actionable data and sophisticated implementation.

    Synacor Inc. (NASDAQ:SYNC), the trusted multiscreen technology and monetization partner for video, internet and communications providers, device manufacturers, and enterprises, announced that it has completed the acquisition of Zimbra, Inc., a global leader in open source email, calendaring, and collaboration software, for a net purchase price of $24.5 million, with Synacor paying $17.3M in cash, issuing 3M shares, 0.6M warrants priced at $3.00 per share, and paying up to $2M in earn-outs over the next 18 months. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Synacor as part of its services.

  • Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified – TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (completed Phase 2), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (preclinical).

    Trevena, Inc. (NASDAQ: TRVN) raised $72.9 million in its follow-on offering at $9.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 975,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering together with its existing cash and investments will be used by Trevena, Inc. to complete Phase 3 development, submit a new drug application, and begin launch preparations for TRV130; to complete its Phase 2b BLAST-AHF study for TRV027; to complete initial Phase 1 studies for TRV250; to continue drug discovery in new therapy areas; and for working capital and general corporate purposes. Needham has now been part of three transactions for Trevena, including its initial public offering in February 2014.

  • Seattle Genetics, Inc. (NASDAQ: SGEN) is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer.

    Seattle Genetics, Inc. (NASDAQ: SGEN) raised $552.0 million in its follow-on offering at $41.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,756,097 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Seattle Genetics to fund the ongoing commercialization of ADCETRIS in the United States and Canada, to fund research and development efforts designed to further expand the ADCETRIS label and to advance its pipeline of product candidates, as well as for general corporate purposes, including working capital. The Company may also use a portion of the net proceeds from this offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property. This is the fourth transaction for Seattle Genetics where Needham has been part of the deal team since 2008.

  • Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox’s lead product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. AQX-1125 has demonstrated preliminary safety and favorable drug properties in multiple preclinical studies and clinical trials. The Firm is currently developing AQX-1125 as an oral, once daily treatment in bladder pain syndrome/interstitial cystitis (BPS/IC). In addition, it is exploring AQX-1125 for atopic dermatitis (AD) in its ongoing Kinship Phase 2 trial. For AQX-1125, the Company retains full worldwide rights and holds patents with terms through at least 2024. Aquinox uses a proprietary screening approach to discover new drug candidates that selectively target SHIP1 to modulate activated immune cells while minimizing their toxicity to normal cells. The Company’s intellectual property covers SHIP1 as a target, the C2 binding domain for screening and the composition of matter for its compounds. Aquinox has an extensive chemical library and several candidate lead compounds that target SHIP1. These compounds have both similar and distinct properties from AQX-1125. The Company believes AQX-1125 is the only SHIP1 activator currently in clinical trials and that no other SHIP1 activator has to date reported data from clinical trials or received marketing approval as a treatment for disease in humans.

    Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) raised $98.04 million in its follow-on offering at $15.50 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 825,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Aquinox Pharmaceuticals for the clinical development of AGX-1125 in BPS/IC, for research, development and manufacturing of product candidates, and for other general corporate purposes.

  • Autonet Mobile Inc. is a world leading application and service provider for cars. Founded in 2005, Autonet Mobile was the first to deliver in-vehicle Wi-Fi with OE compatibility along with new technologies that support applications that allow owners to access their car from their phones to new forms of security.

    Autonet Mobile, a Santa Rosa company that develops devices and software to connect cars to the Internet, has sold its technology to Michigan auto parts giant Lear Corporation (NYSE: LEA). As part of the deal, Lear hired an undisclosed number of Autonet Mobile’s engineering and research and development workers. As part of the agreement announced this week, Lear acquired technology that uses cellular networks to connect on-board vehicle systems with cloud-based applications. Financial terms were not disclosed. Autonet Mobile will continue to use the technology it sold to Lear to support programs with existing customers and to develop new products for the automotive aftermarket, under a license agreement. Needham & Company acted as a financial advisor to Autonet Mobile, Inc..

  • Corium International, Inc. (NASDAQ: CORI) is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience in advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being co-developed with Teva. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders.

    Corium International, Inc. (NASDAQ: CORI) raised $52.0 million in its follow-on offering at $13.00 per share. Needham acted as lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Corium International for general corporate purposes, which may include funding research and development, increasing working capital, acquisitions or investments in businesses, products or technologies that are complementary to Corium’s own businesses and capital expenditures.

  • Dermira, Inc. (NASDAQ: DERM) is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira's portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis; DRM04, in Phase 3 development for the treatment of axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. raised $111.3 million in its follow-on offering at $21.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dermira, Inc. for external research and development expenses associated with the development of Cimzia, DRM04 and DRM01 product candidates, with the balance primarily used to fund internal research and development expenses associated with all product candidates, working capital, capital expenditures and other general corporate purposes.

  • Selectica, Inc. (NASDAQ: SLTC) provides a platform for enterprises worldwide to create, manage, and optimize business relationships with contracts at the core. Selectica helps global companies actively manage their contracts throughout the sales, procurement, and legal life cycles. Selectica's contract management solutions drive business value by assisting organizations in managing contracts profitably, effectively accelerating revenue opportunities, and minimizing risk through compliance. Through IASTA, a Selectica company, we provide leading supply management and spend management solutions, dedicated to empowering sourcing and purchasing professionals. Our blend of acclaimed software and services focus on improving spend analysis, procurement intelligence, sourcing, and supplier life cycle management. Our solutions play a critical role in optimizing business relationships by enhancing supply base insights, improving supplier collaboration and reducing the supply chain risks vital to today's globally-minded enterprise. Selectica also provides a powerful configuration engine, enabling Fortune 500 companies to accelerate revenue by facilitating the optimization of the right combination of products, services, and price.

    Selectica, Inc. (NASDAQ: SLTC) announced that it has completed the acquisition of b-pack, a global leader in purchase-to-pay (P2P) software and services, for approximately $12.33 million in cash and stock. Needham & Company acted as a financial advisor to Selectica, Inc.

  • Genocea Biosciences, Inc. (NASDAQ: GNCA) is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

    Genocea Biosciences, Inc. (NASDAQ: GNCA) raised $50.1 million in its follow-on offering at $13.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Genocea Biosciences to fund the clinical development of GEN-003 and GEN-004, continue investment in new research programs, and the balance for other general corporate purposes.

  • Cara Therapeutics, Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

    Cara Therapeutics, Inc. (NASDAQ: CARA) raised $80.5 million in its follow-on offering at $18.60 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 564,516 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Cara Therapeutics to conduct planned clinical trials of I.V. CR845 and Oral CR845, to fund the research and development of preclinical pipeline, including drug discovery, and for working capital and other general corporate purposes.

  • Intel Corporation (NASDAQ: INTC) is a world leader in computing innovation. The company designs and builds the essential technologies that serve as the foundation for the world’s computing devices. Headquartered in Santa Clara, Calif., Intel today has more than 100,000 employees in 63 countries and serves customers in more than 120 countries. Intel today designs and manufactures a variety of essential technologies, including microprocessors and chipsets and the additional hardware, software, and related services that together serve as the foundation for many of the world’s computing devices. Over the last decade, Intel has evolved from a company that largely serves the PC industry, to a company that increasingly provides the vital intelligence inside all things computing. In fact, one-third of Intel's revenue is associated with products beyond the PC. Hardware and software products by Intel and subsidiaries such as McAfee, power the majority of the world’s data centers, connect hundreds of millions of cellular handsets and help secure and protect computers, mobile devices and corporate and government IT systems. Intel technologies are also inside intelligent systems, such as in automobiles, automated factories and medical devices.

    Intel Corporation (NASDAQ: INTC) issued $7.0 billion principal amount of Convertible Senior Unsecured Notes to finance part of its $16.7 billion takeover of Altera Corp. Needham & Company acted as a co-manager for this transaction.

  • UnboundID provides the industry’s leading software platform for customer identity and access management. Enterprise customers select the UnboundID Platform to modernize traditional Identity and Access Management systems, and enable new customer-facing digital business initiatives that provide real-time personalization and delivery of a consistent customer experience across channels and devices. Some of the world’s largest and most demanding companies in financial services, retail, hospitality, telecommunications and healthcare rely on UnboundID to manage and protect their identity and preference data across application portfolios and systems of engagement. UnboundID customers consistently report a total cost of ownership savings between 25 to 90 percent relative to legacy directory servers, and the company enjoys a 100% customer renewal rate.

    UnboundID, a market leading provider of customer identity and access management software, to help enterprises improve customer engagement, completed its sale to Ping Identity, the leader in Identity Defined Security. Terms of the transaction were not disclosed. The deal puts Ping Identity, which is owned by Vista Equity Partners, firmly in at the intersection of identity and customer engagement and management. The combined company provides Identity and Access Management solutions for the world’s leading companies, including over half of the Fortune 100, and manages over 3 billion identities. Needham & Company acted as the exclusive financial advisor to UnboundID.

  • Ellie Mae, Inc. (NYSE:ELLI) is a leading provider of innovative on-demand software solutions and services for the residential mortgage industry. Mortgage lenders of all sizes use Ellie Mae’s Encompass® all-in-one mortgage management solution, Mavent Compliance Service, and AllRegs research, reference and education resources to improve compliance, loan quality and efficiency across the entire mortgage lifecycle.

    Ellie Mae, Inc. raised $284.63 million in its follow-on offering at $90.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 412,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Ellie Mae, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Argos Therapeutics (NASDAQ: ARGS) is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.

    Argos Therapeutics, Inc. raised $50.0 million in its follow-on offering at $5.50 per share of common stock and accompanying warrants . Needham acted as the lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Argos Therapeutics, Inc. to fund their pivotal Phase 3 ADAPT trial of AGS-003, the ongoing and planned investigator-initiated Phase 2 clinical trials of AGS-003, their share of the expected costs of the leasing, build-out and equipping of a commercial manufacturing facility and activities in preparation for the submission of a BLA to the FDA for AGS-003, and for working capital and other general corporate purposes.

  • Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.

    Nicox S.A. completed the pricing of an offering a reserved capital increase of ordinary shares of the Company to a specific category of investors. The gross proceeds of the financing are approximately €18 million, for a total of 2,064,000 million new shares. Needham acted as lead placement agent for this transaction. The net proceeds from the sale of the Units will be used by Nicox S.A. for clinical development of pipeline candidates (NCX 4251 in blepharitis and NCX 470 in glaucoma), working capital and general corporate purposes.

  • Impinj (NASDAQ: PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers’ licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items’ unique identity, location and authenticity, or Item Intelligence™, to the digital world, which Impinj believes is the essence of the Internet of Things.

    Impinj, Inc. raised $77.3 million in its upsized initial public offering at $14.00 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 720,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Impinj, Inc. to repay $5.0 million of indebtedness under the mezzanine credit facility and the remainder will be used for working capital and other general corporate purposes.

  • FormFactor, Inc. (NASDAQ: FORM) helps semiconductor manufacturers test the integrated circuits (ICs) that power consumer mobile devices, as well as computing, automotive and other applications. The company is one of the world’s leading providers of essential wafer test technologies and expertise, with an extensive portfolio of high-performance probe cards for DRAM, Flash and SoC devices. Customers use FormFactor’s products and services to lower overall production costs, improve their yields and enable complex next-generation ICs. Headquartered in Livermore, California, the company services its customers from a network of facilities in Europe, Asia and North America.

    FormFactor, Inc. (Nasdaq:FORM) announced that it has completed the acquisition of Cascade Microtech, Inc. (NASDAQ: CSCD),a worldwide leader in precision contact, electrical measurement and test of integrated circuits (ICs), optical devices and other small structures, for a net purchase price of $352 million in cash and stock. Needham & Company acted as the exclusive financial advisor and provided a fairness opinion to the Board of Directors of FormFactor, Inc. as part of its services.

  • Selecta Biosciences, Inc. (NASDAQ: SELB) is a clinical-stage biopharmaceutical company developing targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) technology is a highly flexible nanoparticle platform, capable of incorporating a wide range of antigens and immunomodulators, allowing the SVP products to either induce antigen-specific tolerance or activate the immune system. Selecta's focus is on developing and commercializing differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases by mitigating the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Tolerance-inducing SVP products also have potential applications in the treatment of allergies and autoimmune diseases. Selecta is also developing SVP products that activate the immune system to prevent and treat cancer, infections and other diseases. Selecta is based in Watertown, Massachusetts, USA.

    Selecta Biosciences, Inc. raised $74.1 million in its upsized initial public offering at $14.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 289,633 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Selecta Biosciences to support the clinical development of SEL-212, conduct preclinical studies in order to advance the development of Selecta’s other SVP product candidates and for working capital and general corporate purposes.

  • SCYNEXIS, Inc. (NASDAQ: SCYX) is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. SCYNEXIS is developing its lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.

    SCYNEXIS, Inc. raised $22.5 million in its follow-on offering of 9,375,000 shares of its common stock and warrants to purchase 4,218,750 shares of its common stock. The shares and warrants are being sold at a public offering price of $2.40 per share. The shares of common stock and warrants will be issued separately. The warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $3.00 per share. Needham acted as the co-lead manager on the transaction. The net proceeds from the sale of the shares and warrants from the offering will be used by SCYNEXIS, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and strategic acquisitions.

  • Medgenics, Inc. (NYSE: MDGN) is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. Medgenics is also the developer of TARGT™ (Transduced Autologous Restorative Gene Therapy), a proprietary gene therapy platform.

    Medgenics, Inc. raised $21.1 million in its follow-on offering at $5.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 196,363 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Medgenics, Inc. to fund (i) product development activities, including the development of companion diagnostics for existing programs, (ii) patent maintenance fees and intellectual property support, (iii) licensing and research collaborations and (iv) general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses.

  • GigPeak, Inc. (NYSE MKT:GIG) is a leading innovator of semiconductor ICs and software solutions for high-speed connectivity and high-quality video compression over the Network and the Cloud. The focus of the company is to develop and deliver products that enable lower power consumption and faster data connectivity, more efficient use of network infrastructure, broader connectivity to the Cloud, and reduce the total cost of ownership of existing network pipes from the core to the end user. GigPeak addresses both the speed of data transmission and the amount of bandwidth the data consumes within the network, and provides solutions that increase the efficiency of the Internet of Things, leveraging its strength in high-speed connectivity and high quality video compression. The extended product portfolio provides more flexibility to support changing market requirements from ICs and MMICs through full software programmability and cost efficient custom ASICs.

    GigPeak, Inc. raised $28.8 million in its follow-on offering at $2.00 per share. Needham acted as a joint bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,875,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by GigPeak, Inc. for potential acquisitions for strategic growth, including to acquire critical technologies and scalable businesses. It intends to focus on multiple global attractive acquisition targets.

  • Dermira, Inc. (NASDAQ:DERM) is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and DRM01, in Phase 2b development for the treatment of facial acne vulgaris. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. raised $144.9 million in its follow-on offering at $28.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dermira, Inc. will enable the Company to complete and generate topline results from their ongoing Phase 3 clinical trials for Cimzia and their planned Phase 3 clinical trials for DRM01; complete the ARIDO trial and other registration-enabling activities and submit an NDA to the FDA for potential approval related to DRM04; enable UCB to submit a supplemental Biologics License Application to the FDA for potential approval of Cimzia; and commercialize at least one of their product candidates assuming that the Company receives the necessary regulatory approvals.

  • Clearside Biomedical, Inc. (NASDAQ: CLSD), is a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space (SCS™) microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye.

    Clearside Biomedical, Inc. raised $50.4 million in its initial public offering at $7.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 948,843 shares of common stock at the initial public offering price to cover over-allotments.The net proceeds from the sale of the shares will be used by Clearside Biomedical, Inc. for funding of the Company’s pivotal Phase 3 clinical trial of CLS-1001, its Phase 2 clinical trial of CLS-1003 and its preparation of an IND for, and subsequent Phase 1/2 clinical trial of, CLS-1002. The remaining proceeds will be used for the continued research and development of earlier-stage programs, and for working capital and general corporate purposes.

  • RADCOM (NASDAQ: RDCM) is a first-mover and leading provider of NFV-ready service assurance and customer experience management solutions for Communications Service Providers (CSPs). RADCOM's software - MaveriQ - continuously monitors network performance and quality of services, to optimize user experience for CSPs' subscribers. RADCOM specializes in solutions for next-generation mobile and fixed networks, including LTE, VoLTE, IMS and others. MaveriQ enables CSPs to smoothly migrate their networks to NFV by assuring physical, NFV-based and hybrid networks.

    RADCOM Ltd. raised $23.0 million in its follow-on offering at $11.00 per share. Needham acted as the lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 272,727 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by RADCOM for general corporate purposes, which may include financing its operations, capital expenditures and business development.

  • Acacia Communications (NASDAQ: ACIA) develops, manufactures and sells high-speed coherent optical interconnect products that are designed to transform communications networks through improvements in performance, capacity and cost. By converting optical interconnect technology to a silicon-based technology, a process Acacia refers to as the "siliconization of optical interconnect," Acacia is able to offer products that meet the needs of cloud and service provider customers in a simple, open, high-performance form factor that can be easily integrated in a cost-effective manner with existing network equipment.

    Acacia Communications, Inc. raised $119.03 million in its initial public offering at $23.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Acacia Communications for for working capital and general corporate purposes. Acacia Communications will not receive any of the proceeds from any sale of shares by the selling stockholders.

  • Solair is an Italian provider of an innovative IoT software platform to customers across a number of industries, including manufacturing, retail, food & beverage and transportation.

    Solair, an Italian provider of an innovative IoT software platform to customers across a number of industries, including manufacturing, retail, food & beverage and transportation, completed its previously announced sale to Microsoft Corporation (NASDAQ: MSFT), a multinational technology company that develops, manufactures, licenses, supports and sells computer software, consumer electronics and personal computers and services. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to Solair.

  • Rocketick Technologies, Ltd. is an Israel-based pioneer and leading provider of multicore parallel simulation. Rocketick’s market-leading technology achieves linear speed-up by parallelizing simulation on standard x86-based multicore servers, providing automated partitioning across designs and testbenches, and the flexibility to direct simulations to server farm resources ranging from one to 64 cores. It also provides a significant accuracy advantage and enhanced visibility with four-state logic simulation, and reduces host memory footprint by 2-3X for gate-level designs.

    Rocketick Technologies, Ltd., an Israel-based pioneer and leading provider of multicore parallel simulation, completed its previously announced sale to Cadence Design Systems, Inc. (NASDAQ: CDNS), a technology company that enables global electronic design innovation and plays an essential role in the creation of today's integrated circuits and electronics. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to Rocketick Technologies, Ltd..

  • Aeglea (NASDAQ: AGLE) is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

    Aeglea BioTherapeutics, Inc. raised $54.82 million in its upsized initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 481,940 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Aeglea BioTherapeutics, Inc. for general corporate purposes including working capital, product development and operating expenses.

  • Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), with locations in Ewing, N.J., and Vancouver, B.C., is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations of anti-cancer drugs, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensuring exposure of this ratio to the tumor. Celator's lead product is VYXEOS™ (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin in Phase 3 clinical testing for the treatment of acute myeloid leukemia. We have also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. More recently, the Company has advanced its CombiPlex platform and broadened its application to include molecularly targeted therapies.

    Celator Pharmaceuticals, Inc. raised $43.7 million in its follow-on offering at $9.50 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Celator Pharmaceuticals, Inc. to fund initial launch activities, commercialization of VYXEOS, advance the pipeline of clinical stage assets and for general corporate purposes.

  • ANADIGICS, Inc. (NASDAQ: ANAD) designs and manufactures innovative radio frequency (RF) solutions for the growing CATV infrastructure, small-cell, WiFi, and cellular markets. Headquartered in Warren, NJ, ANADIGICS offers RF products with exceptional reliability, performance and integration to deliver a unique competitive advantage to OEMs and ODMs for infrastructure and mobile applications. The Company’s award-winning solutions include line amplifiers, upstream amplifiers, power amplifiers, front-end ICs, front-end modules and other RF components.

    ANADIGICS, Inc. (NASDAQ: ANAD), a world leader in radio frequency (RF) solutions, completed its previously announced sale to II‐VI Incorporated (NASDAQ: IIVI), a leader in engineered materials and optoelectronic components for approximately $78.2 million in cash. Needham & Company acted as the exclusive financial advisor to ANADIGICS, Inc.

  • IntegriChain is the leading channel management cloud used by life sciences suppliers, including nine of the top 10 pharmaceutical manufacturers, to drive channel collaboration and to improve the efficiency of how products reach customers. Pharmaceutical, biopharm/specialty pharma, generics, and consumer health suppliers use IntegriChain to manage their supply chain relationships, inventories, and orders across a vast network of retailers, ecommerce, and distributors. As a suite of informed applications and analytics built on top of aggregated channel inventory and point-of-sale (POS) data, IntegriChain provides customer operations, national accounts, and finance teams with a collaborative, agile, and mobile alternative to ERP and homegrown systems. By embedding big-data customer insights into daily business processes, IntegriChain helps control the high cost of product distribution while improving product availability, ensuring a higher level of revenue predictability and maximizing distribution investment. More than $200 billion in annual U.S. commerce and 2 billion transactions flow through the IntegriChain Cloud annually. IntegriChain is backed by Accel-KKR, a leading technology private equity firm.

    IntegriChain, the leading channel management cloud used by life sciences suppliers has received a strategic equity investment from Accel-KKR, a technology-focused investment firm with $4.0 billion in capital commitments to its current funds. Under the terms of the investment, Accel-KKR will acquire 100% of the equity not held by members of IntegriChain's management team. Needham & Company acted as the exclusive financial advisor to IntegriChain.

  • ThermiGen LLC is a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. The Thermi flagship product is the ThermiRF®, Temperature Controlled Radio Frequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF®, is an advanced technology using finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market.

    ThermiGen LLC, a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications, completed its previously announced sale to Almirall, S.A., a global pharmaceutical company based in Barcelona, Spain. In September 2015, Almirall acquired a minority stake in ThermiGen for $5 million representing 7.7% of the share capital of the company and paid $2.5 million in exchange of a call option right to acquire up to 100% of the company for an Enterprise Value of approximately $80 million. The call option to acquire 100% of the share capital of ThermiGen LLC was exercised by Almirall. Needham & Company acted as the exclusive financial advisor to ThermiGen LLC.

  • PMC (NASDAQ: PMCS) is the semiconductor and software solutions innovator transforming networks that connect, move and store big data. Building on a track record of technology leadership, PMC is driving innovation across storage, optical and mobile networks. PMC's highly integrated solutions increase performance and enable next-generation services to accelerate the network transformation.

    PMC-Sierra, Inc., a leading innovator of energy-saving films and glass products for automotive and architectural markets, completed its previously announced sale to Microsemi Corporation (Nasdaq: MSCC) ("Microsemi"), a leading provider of semiconductor solutions differentiated by power, security, reliability and performance. Under the terms of the agreement, PMC-Sierra's shareholders have received $9.22 in cash and 0.0771 of a share of Microsemi common stock for each share of PMC common stock through an exchange offer. Needham & Company acted as a financial advisor to PMC-Sierra, Inc.

  • Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceutical, Inc. raised $55.0 million in its follow-on offering at $20.00 per share. Needham acted as co-lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia has completed Phase 2 development of its lead product candidate, vadadustat (formerly AKB-6548), an oral therapy for the treatment of anemia related to CKD in both non-dialysis and dialysis patients. Enrollment in the PRO2TECT™ Phase 3 program in non-dialysis patients commenced in late 2015 and the INNO2VATE™ Phase 3 program in dialysis-dependent CKD patients is expected to commence in 2016.

    Akebia Therapeutics, Inc. raised $65.3 million in its follow-on offering at $9.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. offering to fund continued clinical development of vadadustat in patients with anemia secondary to chronic kidney disease (CKD), including to prepare, initiate and conduct its PRO2TECT™ Phase 3 program and to prepare and initiate its planned INNO2VATE™ Phase 3 program, to advance AKB-6899 through Phase 1 development in oncology, and the remainder for working capital and other general corporate purposes.

  • ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which we have submitted a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA and which has the potential to be the first drug approved in the United States for this condition. The FDA has classified the NUPLAZID NDA as having Priority Review status. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain.

    ACADIA Pharmaceuticals Inc. raised $300.0 million in its follow-on offering at $29.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals Inc. . to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

  • Cempra, Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C.

    Cempra, Inc. raised $100.0 million in its follow-on offering at $24.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Cempra, Inc. to fund the commercial launch of solithromycin in community acquired bacterial pneumonia (CABP) in the U.S., subject to the drug receiving FDA approval for such an indication, research and development activities, including the continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in acute bacterial skin and skin structure infections (ABSSSI) and also for the chronic oral treatment of refractory infections in bones and joints, as well as for working capital and general corporate and administrative expenses.

  • Yirendai (NYSE: YRD) is a leading online consumer finance marketplace in China connecting investors and individual borrowers. The Company provides an effective solution to address largely underserved investor and individual borrower demand in China through an online platform that automates key aspects of its operations to efficiently match borrowers with investors and execute loan transactions. Yirendai deploys a proprietary risk management system, which enables the Company to effectively assess the creditworthiness of borrowers, appropriately price the risks associated with borrowers, and offer quality loan investment opportunities to investors. Yirendai's online marketplace provides borrowers with quick and convenient access to consumer credit at competitive prices and investors with easy and quick access to an alternative asset class with attractive returns.

    Yirendai Ltd. raised $75 million in its initial public offering at $10.00 per share. Needham acted as a passive bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Yirendai Ltd. for general corporate purposes, which may include investment in product development, sales and marketing activities, technology infrastructure, capital expenditures, improvement of corporate facilities and other general and administrative matters. The company may also use a portion of these proceeds for the acquisition of, or investment in, technologies, solutions or businesses that complement the company’s business.

  • Pertino is a new way to WAN for the mobile and cloud era—secure, software-defined and delivered as a service. Mobile and cloud technologies are transforming IT, resulting in a hybrid IT model where distributed workforces and workloads are reliant on the Internet. Our Cloud Network Engine platform enables enterprises to build and manage private cloud networks that overlay the public Internet, securely connecting people, devices and resources anywhere. With AppScape, our network services app store, Pertino cloud networks can be extended with enterprise-level visibility, security and control services. This modern approach to networking combines the power and pervasiveness of the cloud with SDN and virtualization technologies to eliminate cost and complexity. Finally, a WAN that is cloud-agile and works the way organizations work today, without hardware, hassles, or high costs. Founded in 2011, Pertino is venture funded by premier firms and headquartered in Los Gatos, California.

    Pertino, a privately-held Silicon Valley company that has pioneered the use of software-defined networking to deliver cloud-based networks as-a-service for enterprise and SMB customers worldwide, completed its previously announced sale to Cradlepoint, the global leader in software-defined 4G LTE network solutions for enterprises. The terms of the transaction were not disclosed. Needham & Company acted as the exclusive financial advisor to Pertino.

  • The Chinese consortium of investors was led by SummitView Capital and includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management. Summitview Capital is a private equity firm specializing in buyouts. It focuses on technology, media and telecommunications, clean technology, semiconductors, and modern information service industry. Summitview Capital is based in Shanghai China, with an additional office in Changzhou, China.

    A Chinese consortium of investors led by SummitView Capital and that includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management announced that it has completed the acquisition of Integrated Silicon Solution, Inc. (NASDAQ: ISSI), a global fabless semiconductor company, for a net purchase price of $782.6 million in cash. Needham & Company acted as a financial advisor to the Chinese consortium.

  • Inphi Corporation (NYSE: IPHI) is a leading provider of high-speed, mixed-signal semiconductor solutions for the communications, computing and data center markets. Inphi’s end-to-end data transport platform delivers high signal integrity at leading-edge data speeds, addressing performance and bandwidth bottlenecks in networks, from fiber to memory. Inphi’s solutions minimize latency in computing environments and enable the rollout of next-generation communications infrastructure. Inphi’s solutions provide a vital interface between analog signals and digital information in high-performance systems, such as telecommunications transport systems, enterprise networking equipment, enterprise and data center servers, and storage platforms.

    Inphi Corporation issued $230.0 million principal amount of Convertible Senior Notes due 2020. The size of the offering was increased to $200.0 from the previously announced $150.0 million aggregate principal amount. Prior to June 1, 2020, the notes will be convertible only under certain circumstances and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The initial conversion rate for the notes will be 24.8988 shares per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $40.16 per share, and will be subject to adjustment upon the occurrence of certain events. The initial conversion price represents a conversion premium of approximately 35.0% over the last reported sale price of $29.75 per share of Inphi's common stock on The New York Stock Exchange on December 2, 2015. Inphi will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. In addition, holders may require Inphi to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. The underwriters fully exercised their option to purchase an additional $30 million in aggregate principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction.

  • Instructure, Inc. (NYSE: INST) is a leading software-as-a-service (SaaS) technology company that makes software that makes people smarter. With a vision to help maximize the potential of people through technology, Instructure created Canvas and Bridge to enable organizations everywhere to easily develop, deliver and manage engaging face-to-face and online learning experiences. To date, Instructure has connected millions of teachers and learners at more than 1,800 educational institutions and corporations throughout the world.

    Instructure, Inc. raised $81.0 million in its initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 660,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Instructure, Inc. for general corporate purposes, including working capital, sales and marketing activities, research and development activities, general and administrative matters and capital expenditures. They may also use a portion of the net proceeds from this offering for acquisitions of, or investments in, technologies, solutions or businesses that complement the business.

  • Xoom Corporation (NASDAQ: XOOM) is a leading digital money transfer provider that enables consumers to send money, pay bills and send mobile reloads to family and friends around the world in a secure, fast and cost-effective way, using their mobile phone, tablet or computer. During the 12 months ended March 31, 2015, Xoom’s more than 1.3 million active customers sent approximately $7.0 billion with Xoom.

    Xoom Corporation, a digital money transfer provider, completed its previously announced sale to PayPal, Inc. (NASDAQ: PYPL), a provider of a worldwide online payments system. In accordance with the terms of the acquisition agreement announced on July 1, 2015, PayPal acquired all of the outstanding shares of Xoom for $25 per share in cash. Xoom will operate as a separate service within PayPal. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Xoom Corporation as part of its services.

  • Xtera Communications, Inc. (NASDAQ: XCOM) is a leading provider of high-capacity, cost-effective optical transport solutions, supporting the high growth in global demand for bandwidth. Xtera sells solutions to telecommunications service providers, content service providers, enterprises and government entities worldwide. Xtera’s proprietary Wise RamanTM optical amplification technology leads to capacity and reach performance advantages over competitive products. Xtera’s solutions enable cost-effective capacity to meet customers’ bandwidth requirements of today and to support their increasing bandwidth demand fueled by the development of data centers and related cloud-based services.

    XTERA Communications Inc. raised $25.0 million in its offering at $5.00 per share. Needham acted as the lead bookrunner on the transaction. The net proceeds from the sale of the shares will be used by XTERA Communications Inc. for working capital and other general corporate purposes, including to finance our expected growth, develop new products or fund capital expenditures. The Company may also use a portion of the net proceeds to repay borrowings under its credit facility or term loan, or to expand its existing business through acquisitions of other businesses, products or technologies.

  • LendingTree, Inc. (NASDAQ: TREE) operates a leading online loan marketplace and provides consumers with an array of online tools and information to help them find the best loans for their needs. The Company's online marketplace connects consumers with multiple lenders that compete for their business, empowering consumers as they comparison-shop across a full suite of loans and credit-based offerings. The Company provides access to lenders offering home loans, home equity loans/lines of credit, reverse mortgages, personal loans, auto loans, small business loans, credit cards, student loans and more.

    LendingTree, Inc. raised $112.41 million in its follow-on offering at $115.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 127,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by LendingTree, Inc. for general corporate purposes, including but not limited to, working capital and potential acquisitions.

  • iboss Cybersecurity defends today’s large, distributed organizations against targeted cyber threats which lead to data loss, with the iboss next-gen Secure Web Gateway Platform, leveraging innovative cloud architecture and patented advanced threat defense technologies. iboss advanced solutions deliver unparalleled visibility across all inbound/outbound data channels, and include security weapons that reveal blind spots, detect breaches and minimize the consequences of data exfiltration. With leading threat protection and unsurpassed usability, iboss is trusted by thousands of organizations and millions of users.

    iBoss, Inc. raised $35.0 million in Series A funds from Goldman Sachs’ Private Capital Investing group. The new financing will allow iboss to aggressively develop groundbreaking technology, including the rollout of its next-generation cloud platform, while continuing to expand globally. Needham acted as the sole placement agent for this transaction.

  • Adesto Technologies Corporation (NASDAQ: IOTS) offers the world’s lowest power memory solutions unleashing innovation for a new class of connected applications and previously unimagined devices. The company has designed and built a portfolio of innovative products, including Fusion Serial Flash, DataFlash® and Mavriq™ serial memory. Adesto holds more than 100 patents with dozens more in process and is working with visionary companies across various industries to deploy its technology to the market.

    Adesto Technologies Corporation raised $25.0 million in its initial public offering at $5.00 per share. Needham acted as the lead bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Adesto Technologies Corporation use the net proceeds from this offering for working capital and other general corporate purposes, to acquire or invest in complementary businesses, products, services, technologies or other assets, and for potential pay down of a $15.0 million term loan facility.

  • Intronis provides data protection solutions for small businesses, delivered exclusively through the IT channel. The Intronis ECHOplatform securely protects physical and virtual data with native support for physical imaging,VMware, Hyper-V, Exchange, and SQL, all through a re-brandable central management console that integrates with major RMM and PSA tools. With Intronis' fixed-fee storage pricing per SMB account, IT service providers are able to streamline their pricing strategy and simplify their account management.

    Intronis, Inc. (NASDAQ: SWTX), a leader in providing data protection solutions to managed service providers (MSPs), a fast-growing channel delivering IT services to small and medium-sized businesses, completed its previously announced sale to Barracuda Networks, Inc. (NYSE: CUDA), a provider of cloud-connected security and storage solutions that simplify IT, in an all cash transaction. Needham & Company acted as a financial advisor to Intronis, Inc..

  • Netsertive’s digital marketing intelligence platform empowers brands and local businesses to work together to win local customers. The company’s two complementary solutions, MarketWise™ for Brands and StreetWise™ for Local Businesses, enable cooperative marketing and resource sharing between brands and their local business partners. Both are powered by Netsertive's proprietary learning engine, which combines the company's deep industry experience with the collective intelligence of its extensive network of automotive, IT technology, major appliance, furniture, consumer electronics and healthcare clients to deliver unprecedented campaign speed, performance and value. An award-winning marketing technology company and Google Premier SMB Partner, Netsertive drives local marketing success from campaign enablement through scaled, local execution. Additionally, Netsertive helps brands with their co-op marketing to ensure localized brand compliance, seamless campaign execution and reimbursement tracking for local partners. Founded in 2009 and based in Research Triangle Park, North Carolina, the company has a history of rapid growth, a world-class team and the strength of venture capital funding from top firms RRE Ventures, Harbert Venture Partners, River Cities Capital Funds and Greycroft Partners. Netsertive was named 2014 Software Company of the Year by North Carolina Technology Association and was named among Inc. Magazine’s 500 fastest-growing private companies three years in a row.

    Netsertive raised $15 million in Series C growth financing. River Cities Capital Funds led the round and will be joined by existing investors. The new round will fuel Netsertive’s acceleration in the digital marketing technology arena, as it continues to add major brands for its MarketWise™ solution and local businesses for its StreetWise™ solution. Needham & Company served as exclusive placement agent on this transaction.

  • Sarepta Therapeutics (NASDAQ: SRPT) is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases.

    Sarepta Therapeutics, Inc. (NASDAQ: SRPT) raised $126.8 million in its follow-on offering at $39.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Sarepta Therapeutics, Inc. for product and commercial development, manufacturing, any business development activities and for general corporate purposes.

  • Dot Hill Systems Corp. (NASDAQ: HILL) solves today's storage workload challenges created by the Internet of Things and third platform technologies leveraging its proprietary AssuredSAN family of hybrid storage solutions with RealStor, the next generation real-time storage operating system. In today's interconnected world, Dot Hill storage solutions support people accessing information, and machines collecting sensor data, all in real time. Dot Hill's solutions combine innovative intelligent software with the industry's most flexible and extensive hardware platform and simplified management to deliver best-in-class solutions. Headquartered in Longmont, Colo., Dot Hill has offices and/or representatives in the United States, Europe, and Asia.

    Dot Hill Systems Corp. (NASDAQ: HILL), a leading innovator of energy-saving films and glass products for automotive and architectural markets, completed its previously announced sale to Seagate Technology plc (NASDAQ: STX), a world leader in storage solutionsin an all cash transaction. Needham & Company acted as a financial advisor to Dot Hill Systems and provided a fairness opinion to its Board of Directors as part of its services.

  • Medgenics, Inc. (NASDAQ: MDGN) is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases.

    Medgenics, Inc. raised $46.01 million in its follow-on offering at $6.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 923,250 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Medgenics, Inc. for for product development activities, including (a) the development of technologies acquired in the previously announced acquisition of neuroFix, LLC, (b) patent maintenance fees and intellectual property support, (c) licensing and research collaborations and (d) general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses and making certain payments in connection with the acquisition of neuroFix, LLC, including an expected $2.8 million payment to satisfy a specific corporate milestone payment to the former stockholders of neuroFix, LLC.

  • Ikanos Communications, Inc. (NASDAQ: IKAN) is a leading provider of advanced broadband semiconductor and software products for the connected home. The company’s broadband DSL, communications processors and other offerings power access infrastructure and customer premises equipment for many of the world’s leading network equipment manufacturers and telecommunications service providers.

    Ikanos Communications, Inc. (NASDAQ: IKAN), a high performance broadband networking semiconductor and software provider enabling both central office and home gateway solutions, completed its previously announced sale to Qualcomm Incorporated (NASDAQ: QCOM), a world leader in 3G, 4G and next-generation wireless technologies. Pursuant to the agreement, Qualcomm Atheros, through a wholly-owned subsidiary, acquired all of the issued and outstanding shares of common stock of Ikanos for $2.75 per share in cash, and assumed all outstanding indebtedness at the closing of the transaction. Needham & Company acted as a financial advisor to Ikanos and provided a fairness opinion to the Board of Directors of Ikanos as part of its services. .

  • 2U, Inc. (NASDAQ: TWOU) partners with leading colleges and universities to deliver the world's best online degree programs so students everywhere can reach their full potential. Our Platform, a fusion of cloud-based software-as-a-service technology and technology-enabled services, provides schools with the comprehensive operating infrastructure they need to attract, enroll, educate, support and graduate students globally.

    2U, Inc. (NASDAQ: TWOU) raised $136.9 million in its follow-on offering at $34.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 525,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by 2U, Inc. for general corporate purposes, including expenditures for program marketing, sales, technology, and content development, in connection with new program launches and growing existing programs.

  • Q2 Holdings, Inc. (NASDAQ: QTWO) is a leading provider of secure, cloud-based virtual banking solutions headquartered in Austin, Texas. Q2 enables regional and community financial institutions, or RCFIs, to deliver a robust suite of integrated virtual banking services and engage more effectively with their retail and commercial account holders who expect to bank anytime, anywhere and on any device. Q2 solutions are often the most frequent point of interaction between its RCFI customers and their account holders. As such, Q2 purpose-built its solutions to deliver a compelling, consistent user experience across digital channels and drive the success of its customers by extending their local brands, enabling improved account holder retention and creating incremental sales opportunities.

    Q2 Holdings, Inc. (NASDAQ: QTWO) raised $111.41 million in its follow-on offering at $25.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 569,850 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Q2 Holdings for general corporate purposes and working capital, including to finance their expected growth, develop new technologies, fund capital expenditures, or expand their existing business through investments in or acquisitions of other businesses or technologies.

  • Paylocity Holding Corporation (NASDAQ: PCTY) is a provider of cloud-based payroll and human capital management, or HCM, software solutions for medium-sized organizations. Paylocity's comprehensive and easy-to-use solutions enable its clients to manage their workforces more effectively. Paylocity's solutions help drive strategic human capital decision-making and improve employee engagement by enhancing the human resource, payroll and finance capabilities of its clients.

    Paylocity Holding Corporation (NASDAQ: PCTY) raised $128.0 million in its follow-on offering at $29.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 561,000 shares of common stock at the follow-on offering price to cover over-allotments. The shares of common stock offered by this prospectus are being registered for the account of the selling stockholders named in the prospectus. As a result, all proceeds from the sales of the common stock will go to the selling stockholders and Paylocity will not receive any proceeds from the resale of the common stock by the selling stockholders.

  • Nabriva Therapeutics AG (NASDAQ: NBRV) is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans.

    Nabriva Therapeutics AG (NASDAQ: NBRV) raised $106.1 million in its initial public offering at $10.25 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,350,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Nabriva to complete the clinical development of lefamulin for CABP, to submit applications for marketing approval for lefamulin for CABP in both the United States and Europe, to pursue the clinical development of lefamulin for additional indications, for earlier stage research and development activities and for working capital and other general corporate purposes.

  • Synacor (NASDAQ:SYNC) is the trusted technology development, multiplatform services and revenue partner for video, internet and communications providers, device manufacturers, and enterprises. We deliver modern, multiscreen experiences and advertising to their consumers that require scale, actionable data and sophisticated implementation.

    Synacor Inc. (NASDAQ:SYNC), the trusted multiscreen technology and monetization partner for video, internet and communications providers, device manufacturers, and enterprises, announced that it has completed the acquisition of Zimbra, Inc., a global leader in open source email, calendaring, and collaboration software, for a net purchase price of $24.5 million, with Synacor paying $17.3M in cash, issuing 3M shares, 0.6M warrants priced at $3.00 per share, and paying up to $2M in earn-outs over the next 18 months. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Synacor as part of its services.

  • Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified – TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (completed Phase 2), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (preclinical).

    Trevena, Inc. (NASDAQ: TRVN) raised $72.9 million in its follow-on offering at $9.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 975,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering together with its existing cash and investments will be used by Trevena, Inc. to complete Phase 3 development, submit a new drug application, and begin launch preparations for TRV130; to complete its Phase 2b BLAST-AHF study for TRV027; to complete initial Phase 1 studies for TRV250; to continue drug discovery in new therapy areas; and for working capital and general corporate purposes. Needham has now been part of three transactions for Trevena, including its initial public offering in February 2014.

  • Seattle Genetics, Inc. (NASDAQ: SGEN) is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer.

    Seattle Genetics, Inc. (NASDAQ: SGEN) raised $552.0 million in its follow-on offering at $41.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,756,097 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Seattle Genetics to fund the ongoing commercialization of ADCETRIS in the United States and Canada, to fund research and development efforts designed to further expand the ADCETRIS label and to advance its pipeline of product candidates, as well as for general corporate purposes, including working capital. The Company may also use a portion of the net proceeds from this offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property. This is the fourth transaction for Seattle Genetics where Needham has been part of the deal team since 2008.

  • Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox’s lead product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. AQX-1125 has demonstrated preliminary safety and favorable drug properties in multiple preclinical studies and clinical trials. The Firm is currently developing AQX-1125 as an oral, once daily treatment in bladder pain syndrome/interstitial cystitis (BPS/IC). In addition, it is exploring AQX-1125 for atopic dermatitis (AD) in its ongoing Kinship Phase 2 trial. For AQX-1125, the Company retains full worldwide rights and holds patents with terms through at least 2024. Aquinox uses a proprietary screening approach to discover new drug candidates that selectively target SHIP1 to modulate activated immune cells while minimizing their toxicity to normal cells. The Company’s intellectual property covers SHIP1 as a target, the C2 binding domain for screening and the composition of matter for its compounds. Aquinox has an extensive chemical library and several candidate lead compounds that target SHIP1. These compounds have both similar and distinct properties from AQX-1125. The Company believes AQX-1125 is the only SHIP1 activator currently in clinical trials and that no other SHIP1 activator has to date reported data from clinical trials or received marketing approval as a treatment for disease in humans.

    Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) raised $98.04 million in its follow-on offering at $15.50 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 825,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Aquinox Pharmaceuticals for the clinical development of AGX-1125 in BPS/IC, for research, development and manufacturing of product candidates, and for other general corporate purposes.

  • Autonet Mobile Inc. is a world leading application and service provider for cars. Founded in 2005, Autonet Mobile was the first to deliver in-vehicle Wi-Fi with OE compatibility along with new technologies that support applications that allow owners to access their car from their phones to new forms of security.

    Autonet Mobile, a Santa Rosa company that develops devices and software to connect cars to the Internet, has sold its technology to Michigan auto parts giant Lear Corporation (NYSE: LEA). As part of the deal, Lear hired an undisclosed number of Autonet Mobile’s engineering and research and development workers. As part of the agreement announced this week, Lear acquired technology that uses cellular networks to connect on-board vehicle systems with cloud-based applications. Financial terms were not disclosed. Autonet Mobile will continue to use the technology it sold to Lear to support programs with existing customers and to develop new products for the automotive aftermarket, under a license agreement. Needham & Company acted as a financial advisor to Autonet Mobile, Inc..

  • Corium International, Inc. (NASDAQ: CORI) is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience in advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being co-developed with Teva. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders.

    Corium International, Inc. (NASDAQ: CORI) raised $52.0 million in its follow-on offering at $13.00 per share. Needham acted as lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Corium International for general corporate purposes, which may include funding research and development, increasing working capital, acquisitions or investments in businesses, products or technologies that are complementary to Corium’s own businesses and capital expenditures.

  • Dermira, Inc. (NASDAQ: DERM) is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira's portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis; DRM04, in Phase 3 development for the treatment of axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. raised $111.3 million in its follow-on offering at $21.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dermira, Inc. for external research and development expenses associated with the development of Cimzia, DRM04 and DRM01 product candidates, with the balance primarily used to fund internal research and development expenses associated with all product candidates, working capital, capital expenditures and other general corporate purposes.

  • Selectica, Inc. (NASDAQ: SLTC) provides a platform for enterprises worldwide to create, manage, and optimize business relationships with contracts at the core. Selectica helps global companies actively manage their contracts throughout the sales, procurement, and legal life cycles. Selectica's contract management solutions drive business value by assisting organizations in managing contracts profitably, effectively accelerating revenue opportunities, and minimizing risk through compliance. Through IASTA, a Selectica company, we provide leading supply management and spend management solutions, dedicated to empowering sourcing and purchasing professionals. Our blend of acclaimed software and services focus on improving spend analysis, procurement intelligence, sourcing, and supplier life cycle management. Our solutions play a critical role in optimizing business relationships by enhancing supply base insights, improving supplier collaboration and reducing the supply chain risks vital to today's globally-minded enterprise. Selectica also provides a powerful configuration engine, enabling Fortune 500 companies to accelerate revenue by facilitating the optimization of the right combination of products, services, and price.

    Selectica, Inc. (NASDAQ: SLTC) announced that it has completed the acquisition of b-pack, a global leader in purchase-to-pay (P2P) software and services, for approximately $12.33 million in cash and stock. Needham & Company acted as a financial advisor to Selectica, Inc.

  • Genocea Biosciences, Inc. (NASDAQ: GNCA) is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

    Genocea Biosciences, Inc. (NASDAQ: GNCA) raised $50.1 million in its follow-on offering at $13.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Genocea Biosciences to fund the clinical development of GEN-003 and GEN-004, continue investment in new research programs, and the balance for other general corporate purposes.

  • Cara Therapeutics, Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

    Cara Therapeutics, Inc. (NASDAQ: CARA) raised $80.5 million in its follow-on offering at $18.60 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 564,516 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Cara Therapeutics to conduct planned clinical trials of I.V. CR845 and Oral CR845, to fund the research and development of preclinical pipeline, including drug discovery, and for working capital and other general corporate purposes.

  • Intel Corporation (NASDAQ: INTC) is a world leader in computing innovation. The company designs and builds the essential technologies that serve as the foundation for the world’s computing devices. Headquartered in Santa Clara, Calif., Intel today has more than 100,000 employees in 63 countries and serves customers in more than 120 countries. Intel today designs and manufactures a variety of essential technologies, including microprocessors and chipsets and the additional hardware, software, and related services that together serve as the foundation for many of the world’s computing devices. Over the last decade, Intel has evolved from a company that largely serves the PC industry, to a company that increasingly provides the vital intelligence inside all things computing. In fact, one-third of Intel's revenue is associated with products beyond the PC. Hardware and software products by Intel and subsidiaries such as McAfee, power the majority of the world’s data centers, connect hundreds of millions of cellular handsets and help secure and protect computers, mobile devices and corporate and government IT systems. Intel technologies are also inside intelligent systems, such as in automobiles, automated factories and medical devices.

    Intel Corporation (NASDAQ: INTC) issued $7.0 billion principal amount of Convertible Senior Unsecured Notes to finance part of its $16.7 billion takeover of Altera Corp. Needham & Company acted as a co-manager for this transaction.

Investment Banking